Skip to main content

Table 2 Change in owners’ clinical score between presentation and 12 weeks

From: Evaluation of a spot-on imidacloprid-moxidectin formulation (Advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study

 

Attitudea

Activityb

Regurgitationc

Salivationd

Appetitee

Week 1

Week 12

Week 1

Week 12

Week 1

Week 12

Week 1

Week 12

Week 1

Week 12

Doramectin

5 (3–5)

5 (3–5)

4 (2–5)

5 (2–5)

1.5 (1–4)

1 (1–2)

1 (1–5)

1 (1–5)

5 (1–5)

5 (2–5)

Advocate

3 (1–5)

5 (2–5)

2.5 (1–5)

5 (2–5)

2.5 (1–5)

1 (1–3)

1 (1–5)

1 (1–5)

5 (2–5)

5 (4–5)

  1. a1, very depressed, 5 excellent
  2. b1, normal; 5, severely decreased
  3. c1, none; 5, severe
  4. d1, none; 5, severe
  5. e1, anorectic; 5, excellent